171 related articles for article (PubMed ID: 24399452)
1. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir.
Wind S; Giessmann T; Jungnik A; Brand T; Marzin K; Bertulis J; Hocke J; Gansser D; Stopfer P
Clin Drug Investig; 2014 Mar; 34(3):173-82. PubMed ID: 24399452
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
Brennan BJ; Moreira SA; Morcos PN; Navarro MT; Asthappan J; Goelzer P; Weigl P; Smith PF
Clin Pharmacokinet; 2013 Sep; 52(9):805-13. PubMed ID: 23712757
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
Wind S; Schmid M; Erhardt J; Goeldner RG; Stopfer P
Clin Pharmacokinet; 2013 Dec; 52(12):1101-9. PubMed ID: 23813493
[TBL] [Abstract][Full Text] [Related]
6. Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.
Dickinson L; Winston A; Boffito M; Khoo S; Back D; Siccardi M
J Antimicrob Chemother; 2016 Apr; 71(4):1041-5. PubMed ID: 26712906
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
Wind S; Schnell D; Ebner T; Freiwald M; Stopfer P
Clin Pharmacokinet; 2017 Mar; 56(3):235-250. PubMed ID: 27470518
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers.
la Porte CJ; Colbers EP; Bertz R; Voncken DS; Wikstrom K; Boeree MJ; Koopmans PP; Hekster YA; Burger DM
Antimicrob Agents Chemother; 2004 May; 48(5):1553-60. PubMed ID: 15105105
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers.
Peytavin G; Gautran C; Otoul C; Cremieux AC; Moulaert B; Delatour F; Melac M; Strolin-Benedetti M; Farinotti R
Eur J Clin Pharmacol; 2005 Jun; 61(4):267-73. PubMed ID: 15889300
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir.
Gutierrez MM; Rosenberg J; Abramowitz W
Clin Ther; 2003 Apr; 25(4):1200-10. PubMed ID: 12809966
[TBL] [Abstract][Full Text] [Related]
12. Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.
Kumar P; Gordon LA; Brooks KM; George JM; Kellogg A; McManus M; Alfaro RM; Nghiem K; Lozier J; Hadigan C; Penzak SR
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848011
[TBL] [Abstract][Full Text] [Related]
13. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
15. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Lassen U; Miller WH; Hotte S; Evans TR; Kollmansberger C; Adamson D; Nielsen DL; Spicer J; Chen E; Meyer T; Brown K; Rafi R; Sawyer MB
Cancer Chemother Pharmacol; 2013 Feb; 71(2):543-9. PubMed ID: 23196640
[TBL] [Abstract][Full Text] [Related]
17. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
[TBL] [Abstract][Full Text] [Related]
18. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
[TBL] [Abstract][Full Text] [Related]
19. Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.
Zhang C; Denti P; Decloedt EH; Ren Y; Karlsson MO; McIlleron H
Br J Clin Pharmacol; 2013 Nov; 76(5):741-51. PubMed ID: 23432610
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
Schnell D; Buschke S; Fuchs H; Gansser D; Goeldner RG; Uttenreuther-Fischer M; Stopfer P; Wind S; Petersen-Sylla M; Halabi A; Koenen R
Cancer Chemother Pharmacol; 2014 Aug; 74(2):267-75. PubMed ID: 24906422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]